A biomarker is a molecule employed to evaluate a person’s biological state, the presence of diseases, and the results of treatment. The last ten years have seen rapid advancements in genomics and proteomics, which have improved our understanding of the genetic regulatory mechanisms underlying CNS biomarkers. Proteomics technologies have advanced in many areas of drug discovery and development by comparing healthy and sick tissues. One of the main objectives of proteomics research is the discovery of helpful protein biomarkers in treatments and diagnostics for the central nervous system. The market for central nervous system biomarkers will grow at a strong CAGR of 9.0%, from a value of $4 billion in 2021 to $8.7 billion by 2030.
Key Trends and Opportunities
A rise in disorders linked to sedentary lifestyles and chronic illnesses will fuel growth in the market for central nervous system biomarkers. The incidence of neurological and cardiovascular issues, including blood pressure, diabetes, coronary heart disease, and other conditions, has significantly increased over the past 20 years. The need for central nervous system biomarkers for disease detection and diagnosis is consequently rising.
The global market for central nervous system biomarkers is predicted to be stimulated by rising developments in genomics, proteomics, and imaging systems, as well as by strong R&D given the number of clinical trials, emerging investments from the government and participants, and favorable government policies.
The COVID-19 pandemic has significantly influenced the market for central nervous system biomarkers worldwide. Patients with COVID-19 frequently report having neurological issues. A viral infection of the neurons or supporting cells in the nasal and olfactory organs is the main cause of the common central nervous system disorder, anosmia. The most common sign of central nervous system dysfunction is diffuse encephalopathy. It is most likely brought on by the effects of the severe COVID-19-associated systemic inflammatory condition on the central nervous system. Additionally, both in the early phases of infection and in the management of long-term effects, CSF and plasma biomarkers were crucial in the clinical evaluation of patients with neuro-COVID.
High validation costs, such as sample collection and storage, and unfavorable reimbursement status for biomarker research and discovery could be obstacles for the central nervous system biomarkers market.
In 2020, the safety biomarker market segment held the largest market share. The segment is anticipated to grow as a result of rising preclinical use and rising awareness of regular health checkups during the forecast period. Additionally, a lot of effort is being put into qualifying biomarkers in preclinical and clinical trials to hasten the development of new medications.
According to end users, the aging population and rising cancer incidence as a result of organophosphates are driving the increased demand for CNS biomarkers in diagnostic centers. The identification of various neurological diseases, as well as the tracking of disease progression, require biomarkers. As more tools for early diagnosis are created, the demand for CNS biomarkers in diagnostic labs is anticipated to increase. According to research by Cancer.net, there will be 24,530 adults and 3,460 children under the age of 15 in the United States who will be diagnosed with a brain or spinal cord tumor in 2020. The National Brain Tumor Society predicts that in 2021, there will be about 85,000 more cases of brain tumors.
North America had the largest revenue share in 2020. The market is anticipated to grow due to factors including an increase in R&D spending and rising CNS cancer cases. In 2021, brain cancer will be the second most frequently diagnosed cancer in children and adolescents, according to the American Cancer Society, with a proportion of 27% and 21%, respectively, where CNS biomarkers are used.
Significant players in the region benefit from the constant innovation and development of new technologies and biomarkers by businesses and research institutions. The American Cancer Society reports that as of August 2020, USD 23.1 million had been set aside for clinical and cancer prevention research in the United States related to the brain.
Banyan Biomarkers Inc., Bio-Rad Laboratories, Aposense Ltd., Avacta Life Sciences Limited, Inc., DiaGenic ASA, G-Biosciences, Merck KGaA, and Thermo Fisher Scientific Inc. are the major international players in the central nervous system biomarkers market.